Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Descriptor ID |
D017430
|
MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 | 1996 | 1 | 0 | 1 | 1997 | 0 | 1 | 1 | 1998 | 1 | 1 | 2 | 1999 | 0 | 2 | 2 | 2000 | 0 | 1 | 1 | 2002 | 3 | 0 | 3 | 2003 | 2 | 4 | 6 | 2004 | 0 | 3 | 3 | 2005 | 2 | 2 | 4 | 2006 | 1 | 2 | 3 | 2007 | 1 | 4 | 5 | 2008 | 3 | 4 | 7 | 2009 | 2 | 3 | 5 | 2010 | 2 | 1 | 3 | 2011 | 4 | 3 | 7 | 2012 | 2 | 4 | 6 | 2013 | 1 | 3 | 4 | 2014 | 0 | 5 | 5 | 2015 | 3 | 6 | 9 | 2016 | 5 | 2 | 7 | 2017 | 0 | 2 | 2 | 2018 | 1 | 7 | 8 | 2019 | 0 | 3 | 3 | 2020 | 1 | 3 | 4 | 2021 | 3 | 1 | 4 | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 09; 82(12):1202-1209.
-
Richards TB, Dai S, Gray SC, Hall IJ, Siegel DA. Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018. Urol Oncol. 2022 05; 40(5):192.e19-192.e25.
-
Hanamura T, Christenson JL, O'Neill KI, Rosas E, Spoelstra NS, Williams MM, Richer JK. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models. Breast Cancer Res. 2021 11 04; 23(1):102.
-
Pickles K, Scherer LD, Cvejic E, Hersch J, Barratt A, McCaffery KJ. Preferences for More or Less Health Care and Association With Health Literacy of Men Eligible for Prostate-Specific Antigen Screening in Australia. JAMA Netw Open. 2021 10 01; 4(10):e2128380.
-
Robin TP, Geiger CL, Callihan EB, Kessler ER. Prostate Cancer in Older Adults: Risk of Clinically Meaningful Disease, the Role of Screening and Special Considerations. Curr Oncol Rep. 2021 08 27; 23(11):130.
-
Shahangian S, Sharma KP, Fan L, Siegel DA. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions. Cancer Rep (Hoboken). 2021 08; 4(4):e1365.
-
Shahangian S, Fan L, Sharma KP, Siegel DA. Use of the prostate-specific antigen (PSA) test in the United States for men age =65, 1999-2015: Implications for practice interventions. Cancer Rep (Hoboken). 2021 08; 4(4):e1352.
-
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 04 20; 39(12):1371-1382.
-
Barqawi A, Pessoa RR, Al-Musawi M, MacDermott T, O'Donnell CI. The Impact of Performing a 3D Mapping Biopsy Prior to Primary Cryotherapy for the Treatment of Prostate Cancer. Urology. 2020 10; 144:171-176.
-
Seydafkan S, Michl J, Pincus MR. Unique Features of Prostate Cancer in African American and West Indian Patients Including Diagnosis of High Grade Cancers Using Only Elevated Serum Levels of Prostate Specific Antigen. Ann Clin Lab Sci. 2020 Jul; 50(4):504-511.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|